Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Sijin Wen's publication output changed over time?
ScholarIQpublication output · 2003–2019
Output grew0% over the shown period — from 1 works in 2003 to 1 in 2019.
1
1
1
1
2
1
1
1
1
1
2003200520062007200820092010201220132019
What are the most-cited papers on Sijin Wen?
ScholarIQmost cited works
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam, Susan O’Brien, William G. Wierda, Hagop M. Kantarjian, Sijin Wen, Kim‐Anh Do, Deborah A. Thomas, Jörge E. Cortes, Susan Lerner, Michael J. Keating
Blood. 2008690 CitationsOPEN ACCESS
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Apostolia M. Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Aung Naing, Filip Jankú, Rajyalakshmi Luthra, Ye Yang, Sijin Wen, Donald A. Berry, Razelle Kurzrock
Clinical Cancer Research. 2012542 CitationsOPEN ACCESS
Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia
William G. Wierda, Susan O’Brien, Sijin Wen, Stefan Faderl, Guillermo Garcia‐Manero, Deborah A. Thomas, Kim‐Anh Do, Jörge E. Cortes, Charles Koller, Miloslav Beran, Alessandra Ferrajoli, Francis J. Giles, Susan Lerner, Maher Albitar, Hagop M. Kantarjian, Michael J. Keating
Journal of Clinical Oncology. 2005524 Citations
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
Padmanee Sharma, Yu Shen, Sijin Wen, Sachiko Yamada, Achim A. Jungbluth, Sacha Gnjatic, Dean F. Bajorin, Victor E. Reuter, Harry W. Herr, Lloyd J. Old, Eiichi Sato
Proceedings of the National Academy of Sciences. 2007522 Citations
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz, Paulo M. Hoff, Jeffrey S. Morris, Robert A. Wolff, Cathy Eng, Katrina Y. Glover, R. Adinin, Michael J. Overman, V VALERO, Sijin Wen, Christopher H. Lieu, Shaoyu Yan, Hai T. Tran, Lee M. Ellis, James L. Abbruzzese, John V. Heymach
Journal of Clinical Oncology. 2009487 CitationsOPEN ACCESS
Related on ScholarIQ
West Virginia University
Institution
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Paper
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Paper
Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia
Paper
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
Paper
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Paper